New drug duo tested for Tough-to-Treat leukemia
NCT ID NCT04231851
Summary
This study is testing whether combining two drugs, CPX-351 and glasdegib, is effective for adults with specific, hard-to-treat forms of acute myeloid leukemia (AML) who have not yet received treatment. The main goal is to see how many patients are still in remission and event-free after six months. Researchers will also closely monitor side effects and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.